Ireland-based Jazz Pharmaceuticals Plc is to expand its presence in neuroscience with the acquisition of GW Pharmaceuticals Inc which has pioneered the development and commercialisation of medicines derived from cannabinoids. The transaction is valued at $7.2 billion, or $6.7 billion net of GW Pharma’s cash.
